• In June 2026, Arrowhead Pharmaceuticals announced that the European Commission granted marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome, supported by Phase 3 PALISADE data showing very large median triglyceride reductions and a marked drop in acute pancreatitis risk versus placebo.
• Because REDEMPLO is the first and only siRNA therapy in the European Union for adults with FCS and does not require genetic confirmation of the disease, the approval broadens the eligible patient population and highlights the commercial and scientific potential of Arrowhead’s TRiM™ RNAi platform.
• We’ll now examine how REDEMPLO’s European approval, especially its ability to treat clinically diagnosed FCS patients, reshapes Arrowhead’s investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead, you need to believe that its TRiM RNAi platform can translate into commercially meaningful, approved drugs while the company manages rising costs and partner dependence. The EC approval of REDEMPLO helps de-risk plozasiran in FCS and gives Arrowhead its first marketed product in Europe, but it does not eliminate near term risks around cash burn, reimbursement decisions, and execution on broader cardiometabolic indications that remain key to the story.

Among recent developments, Arrowhead’s June 27 reclassification into larger Russell indices (including the Russell 1000 and Midcap benchmarks) is especially relevant. This shift reflects the company’s move into a more widely followed peer group and may increase passive ownership, potentially amplifying how future clinical, regulatory, and reimbursement updates for REDEMPLO and other TRiM programs feed into short term trading around key catalysts.

Yet even as REDEMPLO’s approval broadens Arrowhead’s opportunity, investors should be aware that reimbursement pressure and payer decisions could...

Arrowhead Pharmaceuticals’ narrative projects $398.8 million revenue and $64.0 million earnings by 2028.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 20% downside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts saw annual revenue falling about 15.9 percent and needing a rich 150 times 2029 earnings, so compared with concerns about reimbursement pressure their view of Arrowhead’s risk reward before the REDEMPLO news was much more pessimistic and is exactly why it can be useful for you to weigh very different scenarios side by side.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth 20% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.